1. Market Research
  2. > Apricus Biosciences, Inc. – Product Pipeline Review – 2013

Apricus Biosciences, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 119 pages

Apricus Biosciences, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Apricus Biosciences, Inc. - Product Pipeline Review - 2013” provides data on the Apricus Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Apricus Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Apricus Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Apricus Biosciences, Inc. - Brief Apricus Biosciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Apricus Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Apricus Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Apricus Biosciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Apricus Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Apricus Biosciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Apricus Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Apricus Biosciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Apricus Biosciences, Inc. and identify potential opportunities in those areas.

Table Of Contents

Apricus Biosciences, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Apricus Biosciences, Inc. Snapshot 7
Apricus Biosciences, Inc. Overview 7
Key Information 7
Key Facts 7
Apricus Biosciences, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Apricus Biosciences, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Apricus Biosciences, Inc. - Pipeline Products Glance 14
Apricus Biosciences, Inc. - Late Stage Pipeline 14
Registration Filed Products/Combination Treatment Modalities 14
Filing Rejected/Withdrawn Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Apricus Biosciences, Inc. - Early Stage Pipeline Products 17
Pre-Clinical Products/Combination Treatment Modalities 17
Apricus Biosciences, Inc. - Drug Profiles 18
(betamethasone + calcipotriene) 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
alprostadil 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
filgrastim 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
fluorouracil 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
insulin human 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
lansoprazole 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
lansoprazole + [doxorubicin] 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
lidocaine 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
paclitaxel 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
rituximab 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
terbinafine 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Apricus Biosciences, Inc. - Pipeline Products by Route of Administration 35
Apricus Biosciences, Inc. - Pipeline Products By Mechanism of Action 36
Apricus Biosciences, Inc. - Recent Pipeline Updates 38
Apricus Biosciences, Inc. - Dormant Projects 48
Apricus Biosciences, Inc. - Company Statement 49
Apricus Biosciences, Inc. - Locations And Subsidiaries 55
Head Office 55
Other Locations and Subsidiaries 55
Apricus Biosciences, Inc. - Key Manufacturing Facilities 56
Apricus Biosciences, Inc., Recent Developments 57
Apricus Biosciences, Inc.- Press Release 57
Nov 22, 2010: Apricus Files Phase III Registration Protocol For PrevOnco For Special Protocol Consideration By FDA 57
Nov 15, 2010: Apricus Biosciences Receives Canadian Approval For Vitaros As First Line Therapy For Erectile Dysfunction 57
Nov 02, 2010: PediatRx launches GRANISOL, the only FDA-approved, ready-to-use oral liquid solution of granisetron 58
Oct 18, 2010: Apricus Bio Receives First Patent Grant For Femprox In Japan 58
Oct 14, 2010: Apricus Bio Announces IND Filing For Nupen 59
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma 59
Jul 29, 2010: PediatRx Acquires Granisol 60
Jun 24, 2010: Nexmed Receives First Patent For Vitaros In Japan 60
Jun 23, 2010: NexMed Receives Screening Acceptance Letter From Health Canada For Vitaros 61
Jun 15, 2010: Nexmed Announces Preclinical Results Of Calcipotri 0.005% And Betamethasone For Treatment Of Psoriasis 61
Jun 10, 2010: Nexmed Provides Update On Canadian Filing For Vitaros 62
May 17, 2010: Nexmed Receives INDA Number For Nexact-Based Alprostadil Treatment For Raynaud's Syndrome From FDA 62
May 12, 2010: NexMed Announces Pre-Clinical Study Results Showing Vitaros Significantly Promotes Wound Healing 62
Apr 26, 2010: Nexmed Receives FDA Clearance For Prevonco Phase II Study As First-Line Therapy For HCC 63
Apr 23, 2010: Nexmed Files CMC Response With Health Canada For Vitaros 63
Apr 22, 2010: NexMed Files CMC Response With Health Canada For Vitaros 64
Mar 29, 2010: Nexmed Files Investigational New Drug Application For Cancer Drug Candidate PrevOnco 64
Mar 29, 2010: Nexmed Files Investigational New Drug Application With FDA For Cancer Drug Candidate 65
Jan 19, 2010: NexMed Provides Updates On Canadian Approval Process For Vitaros 66
Financial Deals Landscape 67
Apricus Biosciences, Inc., Deals Summary 67
Apricus Biosciences, Inc., Pharmaceuticals and Healthcare, Deal Details 69
Asset Transactions 69
Apricus Biosciences Completes Acquisition Of NitroMist Rights From NovaDel Pharma For $0.2 Million 69
Partnerships 71
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 71
Pharmaceutics International Enters Into Collaboration Agreement With NexMed 73
Licensing Agreements 74
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 74
Apricus Biosciences Enters Into Licensing Agreement With Sandoz For Vitaros 76
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For MycoVa 77
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 79
Apricus Biosciences Enters Into Licensing Agreement With Stellar Pharma For MycoVa 80
Apricus Biosciences Enters Into Licensing Agreement With Neopharm For Vitaros 82
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For Vitaros 84
Apricus Biosciences Enters Into Licensing Agreement With Bracco 86
Warner Chilcott Enters Into License Agreement With NexMed 87
Equity Offering 89
Apricus Biosciences Completes Public Offering Of Units For $20 Million 89
Apricus Biosciences Announces Rights Offering 91
Apricus Biosciences Completes Private Placement Of $9.3 Million 93
NexMed Completes Public Offering For $9.34 Million 95
NexMed Completes Private Placement Of Common Stock For $6 Million 97
Debt Offering 99
NexMed Completes Private Placement Of Convertible Notes For $0.75 Million 99
NexMed Completes Convertible Notes Offering Of $5.75 Million 100
Nexmed Completes 8% Senior Secured Notes Offering For $3 Million 102
Asset Transactions 104
Biocodex Acquires Rights To Totect, Anthracycline Extravasation Medicine, From Apricus Biosciences 104
Mist Pharma Acquires Rights To NitroMist From Apricus Biosciences 106
Warner Chilcott Acquires Topical Alprostadil From Nexmed 108
Acquisition 110
Apricus Biosciences Completes Acquisition Of Finesco For Up To $11 Million 110
Apricus Biosciences Completes Acquisition Of Topotarget USA 112
Biotox Sciences Acquires Bio-Quant From Apricus Biosciences 114
NexMed Acquires Bio-Quant 116
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 119
Disclaimer 119



List of Tables

Apricus Biosciences, Inc., Key Information 7
Apricus Biosciences, Inc., Key Facts 7
Apricus Biosciences, Inc. - Pipeline by Indication, 2013 10
Apricus Biosciences, Inc. - Pipeline by Stage of Development, 2013 11
Apricus Biosciences, Inc. - Monotherapy Products in Pipeline, 2013 12
Apricus Biosciences, Inc. - Combination Treatment Modalities in Pipeline, 2013 13
Apricus Biosciences, Inc. - Filed, 2013 14
Apricus Biosciences, Inc. - Filing Rejected/Withdrawn, 2013 15
Apricus Biosciences, Inc. - Phase III, 2013 16
Apricus Biosciences, Inc. - Pre-Clinical, 2013 17
Apricus Biosciences, Inc. - Pipeline By Route of Administration, 2013 35
Apricus Biosciences, Inc. - Pipeline Products By Mechanism of Action, 2013 37
Apricus Biosciences, Inc. - Recent Pipeline Updates, 2013 38
Apricus Biosciences, Inc. - Dormant Developmental Projects,2013 48
Apricus Biosciences, Inc., Subsidiaries 55
Apricus Biosciences, Inc., Key Manufacturing Facilities 56
Apricus Biosciences, Inc., Deals Summary 67
Apricus Biosciences Completes Acquisition Of NitroMist Rights From NovaDel Pharma For $0.2 Million 69
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 71
Pharmaceutics International Enters Into Collaboration Agreement With NexMed 73
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 74
Apricus Biosciences Enters Into Licensing Agreement With Sandoz For Vitaros 76
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For MycoVa 77
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 79
Apricus Biosciences Enters Into Licensing Agreement With Stellar Pharma For MycoVa 80
Apricus Biosciences Enters Into Licensing Agreement With Neopharm For Vitaros 82
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For Vitaros 84
Apricus Biosciences Enters Into Licensing Agreement With Bracco 86
Warner Chilcott Enters Into License Agreement With NexMed 87
Apricus Biosciences Completes Public Offering Of Units For $20 Million 89
Apricus Biosciences Announces Rights Offering 91
Apricus Biosciences Completes Private Placement Of $9.3 Million 93
NexMed Completes Public Offering For $9.34 Million 95
NexMed Completes Private Placement Of Common Stock For $6 Million 97
NexMed Completes Private Placement Of Convertible Notes For $0.75 Million 99
NexMed Completes Convertible Notes Offering Of $5.75 Million 100
Nexmed Completes 8% Senior Secured Notes Offering For $3 Million 102
Biocodex Acquires Rights To Totect, Anthracycline Extravasation Medicine, From Apricus Biosciences 104
Mist Pharma Acquires Rights To NitroMist From Apricus Biosciences 106
Warner Chilcott Acquires Topical Alprostadil From Nexmed 108
Apricus Biosciences Completes Acquisition Of Finesco For Up To $11 Million 110
Apricus Biosciences Completes Acquisition Of Topotarget USA 112
Biotox Sciences Acquires Bio-Quant From Apricus Biosciences 114
NexMed Acquires Bio-Quant 116



List of Figures

Apricus Biosciences, Inc. - Pipeline by Indication, 2013 9
Apricus Biosciences, Inc. - Pipeline by Stage of Development, 2013 11
Apricus Biosciences, Inc. - Monotherapy Products in Pipeline, 2013 12
Apricus Biosciences, Inc. - Combination Treatment Modalities in Pipeline, 2013 13
Apricus Biosciences, Inc. - Pipeline By Route of Administration, 2013 35
Apricus Biosciences, Inc. - Pipeline Products By Mechanism of Action, 2013 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.